Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2010 December;58(6) > Minerva Cardioangiologica 2010 December;58(6):657-76

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  ARRHYTHMIAS 2010 

Minerva Cardioangiologica 2010 December;58(6):657-76

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Management of ventricular arrhythmias

Aronow W. S.

Cardiology Division, Department of Medicine, New York Medical College, Valhalla, New York, NY, USA


PDF


Underlying causes of ventricular tachycardia (VT) or complex ventricular arrhythmias (VA) should be treated if possible. Anti-arrhythmic drugs should not be used to treat asymptomatic patients with complex VA and no heart disease. Beta blockers are the only antiarrhythmic drugs that have been documented to reduce mortality in patients with VT or complex VA. Radiofrequency catheter ablation of VT has been beneficial in treating selected patients with arrhythmogenic foci of monomorphic VT. The automatic implantable cardioverter-defibrillator (AICD) is the most effective treatment for patients with life-threatening VT or ventricular fibrillation. The American College of Cardiology/American Heart Association class I indications for an AICD are discussed. Other indications for an AICD are discussed. Patients with AICDs should be treated with biventricular pacing, not with dual-chamber rate-responsive pacing at a rate of 70/minute. Patients with AICDs should be treated with beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin blockers.

top of page